Certara Announces 2026 Certainty Event

Following this year’s theme, “Right from the Start”, the event will bring together leading experts across the life sciences to discuss the future of AI-enabled technologies from discovery to development

ペンシルベニア州ラドナー2026年3月9日：バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in model-informed drug development, today announced Certainty 2026 will be held April 14-15 in Boston, Massachusetts. Now in its third year, the conference brings together a community of leaders across biosimulation, clinical pharmacology, regulatory science and clinical data science to bring greater clarity and confidence to every stage of drug discovery and development.

This year’s keynote speaker, Dr. David Fajgenbaum, MBA, MSc., co-founder and president of Every Cure and a physician-scientist at the University of Pennsylvania, is pioneering a new model of unlocking life-saving treatments. After discovering the therapy that saved his own life, he’s advanced 13 additional treatments and secured more than $100 million to scale globally. At the event, he will talk about the role that quantitative science can play in supporting this mission to bring hope to patients.

Certainty 2026 will explore how AI-enabled modeling and simulation is improving decision-making at every stage of R&D. The event will feature in-depth tracks and interactive sessions to further explore specific interests across the entire lifecycle. Tracks include:

• AI-Enabled Modeling and Simulation from Strategy to Approval: explore how empirical PK/PD methods like non-compartmental analysis (NCA) and popPK are complementing mechanistic approaches like PBPK and QSP to answer the most daunting challenges in development, from optimal first-in-human dosing to presenting clinical pharmacology evidence effectively in your regulatory submissions.
• P21 Live: Digital Data Flow Optimization: follow the flow of data from protocol all the way to submission, from mapping specs and APIs to the progress of our solution for metadata management. This track features several customer presentations from AstraZeneca and Merck, as well as an update on changing regulatory expectations and the tie to standards and submission workflows. Attendees will also engage in rapid-fire roundtables, sharing tactics on automation, analytics, and readiness.
• Phoenix User Meeting: explore how empirical pharmacokinetic/pharmacodynamic (PK/PD) methods work alongside in silico approaches and get an interactive look at new features, roadmap, and AI’s expanding role in modeling and reporting. Get a sneak peek at the future of Phoenix Cloud for population pharmacokinetic modeling, explore the next era of innovation in PK/PD, and gather with other users to provide feedback and connect with Phoenix product experts.
• QSP Summit: learn via featured case studies across disease areas how QSP (Quantitative Systems Pharmacology) is transforming MIDD through computational modeling, AI integration, and mechanistic insights, and take part in forward-looking discussions on regulatory adoption and the future of predictive modeling. Keynote presenter Vaishali Sahasrabudhe, Head of Pharmacometrics and Systems Pharmacology in Translational Clinical Sciences at Pfizer, will speak on Integrating Disease Biology, Pharmacology and Data to Inform Drug Development Decisions.
• Discovery: Intelligent Lead Optimization with Chemaxon and D360: discuss the explosion of new modalities and the expanding scope of informatics as AI closes gaps between chemistry, safety, and efficacy, including how predictive modeling is reshaping compound design and enabling a clearer view downstream in drug discovery. The track will explore what it takes for informatics solutions to keep pace with increasing molecular complexity and data diversity.
• PBPK (Physiologically-based Pharmacokinetic) Modeling Workshop: see how the Simcyp Simulator informs decisions for first-in-human dosing to formulation, drug–drug interactions, and special population optimization. Expert talks and case studies will offer practical insights to strengthen confidence in model-informed development.

Certainty brings together scientists and drug developers from more than 80 biopharmaceutical companies. For more information about Certara’s event schedule, including the Certainty APAC and EMEA events, please visit: https://certainty.certara.com/